Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
2.

Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A.

Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.

3.

Neoantigen-based cancer immunotherapy.

Bobisse S, Foukas PG, Coukos G, Harari A.

Ann Transl Med. 2016 Jul;4(14):262. doi: 10.21037/atm.2016.06.17. Review.

4.

Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.

Sandri S, Bobisse S, Moxley K, Lamolinara A, De Sanctis F, Boschi F, Sbarbati A, Fracasso G, Ferrarini G, Hendriks RW, Cavallini C, Scupoli MT, Sartoris S, Iezzi M, Nishimura MI, Bronte V, Ugel S.

Cancer Res. 2016 May 1;76(9):2540-51. doi: 10.1158/0008-5472.CAN-15-2318.

5.

High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools.

Chevalier MF, Bobisse S, Costa-Nunes C, Cesson V, Jichlinski P, Speiser DE, Harari A, Coukos G, Romero P, Nardelli-Haefliger D, Jandus C, Derré L.

Oncoimmunology. 2015 May 27;4(10):e1029702. eCollection 2015 Oct.

6.

Personalized approaches to active immunotherapy in cancer.

Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE.

Biochim Biophys Acta. 2016 Jan;1865(1):72-82. doi: 10.1016/j.bbcan.2015.07.004. Epub 2015 Aug 1. Review.

PMID:
26241169
7.

PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models.

Zuccolotto G, Fracasso G, Merlo A, Montagner IM, Rondina M, Bobisse S, Figini M, Cingarlini S, Colombatti M, Zanovello P, Rosato A.

PLoS One. 2014 Oct 3;9(10):e109427. doi: 10.1371/journal.pone.0109427. eCollection 2014.

8.

Functional avidity-driven activation-induced cell death shapes CTL immunodominance.

Dalla Santa S, Merlo A, Bobisse S, Ronconi E, Boldrin D, Milan G, Barbieri V, Marin O, Facchinetti A, Biasi G, Dolcetti R, Zanovello P, Rosato A.

J Immunol. 2014 Nov 1;193(9):4704-11. doi: 10.4049/jimmunol.1303203. Epub 2014 Sep 22.

9.

A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype.

Occhi G, Regazzo D, Trivellin G, Boaretto F, Ciato D, Bobisse S, Ferasin S, Cetani F, Pardi E, Korbonits M, Pellegata NS, Sidarovich V, Quattrone A, Opocher G, Mantero F, Scaroni C.

PLoS Genet. 2013 Mar;9(3):e1003350. doi: 10.1371/journal.pgen.1003350. Epub 2013 Mar 21.

10.

The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression.

Schiavi F, Demattè S, Cecchini ME, Taschin E, Bobisse S, Del Piano A, Donner D, Barbareschi M, Manera V, Zovato S, Erlic Z, Savvoukidis T, Barollo S, Grego F, Trabalzini F, Amistà P, Grandi C, Branz F, Marroni F, Neumann HP, Opocher G.

J Clin Endocrinol Metab. 2012 Apr;97(4):E637-41. doi: 10.1210/jc.2011-2597. Epub 2012 Mar 28.

PMID:
22456618
11.

MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.

Burnichon N, Cascón A, Schiavi F, Morales NP, Comino-Méndez I, Abermil N, Inglada-Pérez L, de Cubas AA, Amar L, Barontini M, de Quirós SB, Bertherat J, Bignon YJ, Blok MJ, Bobisse S, Borrego S, Castellano M, Chanson P, Chiara MD, Corssmit EP, Giacchè M, de Krijger RR, Ercolino T, Girerd X, Gómez-García EB, Gómez-Graña A, Guilhem I, Hes FJ, Honrado E, Korpershoek E, Lenders JW, Letón R, Mensenkamp AR, Merlo A, Mori L, Murat A, Pierre P, Plouin PF, Prodanov T, Quesada-Charneco M, Qin N, Rapizzi E, Raymond V, Reisch N, Roncador G, Ruiz-Ferrer M, Schillo F, Stegmann AP, Suarez C, Taschin E, Timmers HJ, Tops CM, Urioste M, Beuschlein F, Pacak K, Mannelli M, Dahia PL, Opocher G, Eisenhofer G, Gimenez-Roqueplo AP, Robledo M.

Clin Cancer Res. 2012 May 15;18(10):2828-37. doi: 10.1158/1078-0432.CCR-12-0160. Epub 2012 Mar 27.

12.

Is genetic screening indicated in apparently sporadic pheochromocytomas and paragangliomas?

Iacobone M, Schiavi F, Bottussi M, Taschin E, Bobisse S, Fassina A, Opocher G, Favia G.

Surgery. 2011 Dec;150(6):1194-201. doi: 10.1016/j.surg.2011.09.024.

PMID:
22136840
13.

Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma.

Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, Landa I, Leandro-García LJ, Letón R, Honrado E, Ramos-Medina R, Caronia D, Pita G, Gómez-Graña A, de Cubas AA, Inglada-Pérez L, Maliszewska A, Taschin E, Bobisse S, Pica G, Loli P, Hernández-Lavado R, Díaz JA, Gómez-Morales M, González-Neira A, Roncador G, Rodríguez-Antona C, Benítez J, Mannelli M, Opocher G, Robledo M, Cascón A.

Nat Genet. 2011 Jun 19;43(7):663-7. doi: 10.1038/ng.861.

PMID:
21685915
14.

Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.

Merlo A, Turrini R, Bobisse S, Zamarchi R, Alaggio R, Dolcetti R, Mautner J, Zanovello P, Amadori A, Rosato A.

J Immunol. 2010 May 15;184(10):5895-902. doi: 10.4049/jimmunol.0902850. Epub 2010 Apr 12.

15.

Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.

Bobisse S, Rondina M, Merlo A, Tisato V, Mandruzzato S, Amendola M, Naldini L, Willemsen RA, Debets R, Zanovello P, Rosato A.

Cancer Res. 2009 Dec 15;69(24):9385-94. doi: 10.1158/0008-5472.CAN-09-0494.

16.

A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis.

Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, Parenti AR, Rosato A, Bicciato S, Balmain A, Piccolo S.

Cell. 2009 Apr 3;137(1):87-98. doi: 10.1016/j.cell.2009.01.039.

17.

A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity.

Banzato A, Bobisse S, Rondina M, Renier D, Bettella F, Esposito G, Quintieri L, Meléndez-Alafort L, Mazzi U, Zanovello P, Rosato A.

Clin Cancer Res. 2008 Jun 1;14(11):3598-606. doi: 10.1158/1078-0432.CCR-07-2019.

18.

Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer.

Sebestyén Z, Schooten E, Sals T, Zaldivar I, San José E, Alarcón B, Bobisse S, Rosato A, Szöllosi J, Gratama JW, Willemsen RA, Debets R.

J Immunol. 2008 Jun 1;180(11):7736-46.

19.

T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy.

Bobisse S, Zanovello P, Rosato A.

Expert Opin Biol Ther. 2007 Jun;7(6):893-906. Review.

PMID:
17555374
20.

The scaffold protein Cybr is required for cytokine-modulated trafficking of leukocytes in vivo.

Coppola V, Barrick CA, Bobisse S, Rodriguez-Galan MC, Pivetta M, Reynolds D, Howard OM, Palko ME, Esteban PF, Young HA, Rosato A, Tessarollo L.

Mol Cell Biol. 2006 Jul;26(14):5249-58.

Supplemental Content

Loading ...
Support Center